Drugs of Abuse Testing - Global ﾂ鮓ｹﾔｭｴｴ Outlook (2017-2026)

Publication ID:

SMRC0418065

Publication Date:

April 1, 2018

Pages:

148

Publisher:

Stratistics MRC

Countries:

Global [1]

USD 4,150.00

Drug Discovery [2]

Pharma & Healthcare [3]

Description:

The Global Drug Abuse Testing devices market is accounted for $ 3856.3 million in 2017 and is expected to reach $ 7149.5 million by 2026 growing at a CAGR of 7.1% during the forecast period. The factor which may influence the growth of the market is increased use of drug testing at organizational level, increased production and trade of illicit drugs worldwide and others. The market is growing due to technological advancements taking place that increase sensitivity, reduce consumption of time, and facilitate detection of newly developed designer drugs. The increased use of drug of abuse tests for legal and medical purposes has made it imperative to produce results with high confidence levels. As a result, improvement can be observed in various facets such as chemistry, materials, device and equipment. However, increase in drug variety creates difficulty in identifying drug level in drug testing devices, this set as major restraints for the market.

Drug of abuse testing is required to identify the presence of various drugs in person窶冱 body through different samples such as hair, urine, blood, saliva, etc. It is important in order to suggest with suitable medical treatment to the person or to screen or monitor for the use of illegal drugs. The drug of abuse testing can be performed for a variety of reasons such as Employment drug testing, medical screening, athletics testing, and legal forensic information among others. Medical screening for drugs is performed to decide the combination of drugs a person may have consumed in order to offer appropriate treatment.

Amongst Product, the chromatographic devices segment acquired considerable share. Chromatography is the separation and identification technique. Structurally or chemically like components of homogeneous mixture can be divided using this procedure. Separation is based upon component窶冱 relative ability to absorb or separation between stationary phase and the mobile phase. In all the chromatographic techniques, the sample is dissolve in a mobile phase which may be a supercritical fluid, a gas, or a liquid. Geographically, North America has been the largest market with the U.S. being the larger contributor to the regional market, as compared to rest of North America. The important position of the North American market is mostly due to the increased accessibility of illicit drugs, rising workplace monitoring for utilization of illicit drugs and increased drug trafficking in the region.

Some of the key players in Drugs of abuse testing are Atlas link biotech co ltd, Backman Coulter inc, 1ST Step detect associates llc, Biophor diagnostics inc, Abbott Laboratories, Bio-Medical products Corp, Accutech llc, Bio-Rad Laboratories inc, Alere Inc, Bioscan Screening Systems inc, Alfa Scientific Designs inc, Branan Medical Corp, Amedica Biotech inc, Confirm Biosciences, American Biomedica Corpation and Devon Medical Products.

Products Covered:
窶｢ Analyzers
窶｢ Immunoassays Analyzers
窶｢ Chromatographic Devices
窶｢ Breath Analyzers
窶｢ Rapid Testing Devices
窶｢ Urine Testing Devices
窶｢ Oral Fluid Testing Devices
窶｢ Consumables
窶｢ Fluid Collection Devices
窶｢ Other Products

Samples Covered:
窶｢ Saliva
窶｢ Breath
窶｢ Urine
窶｢ Blood
窶｢ Hair & Sweat

Testings Covered:
窶｢ Work Place Screening
窶｢ Pain Management Testing
窶｢ Criminal Justice Testing
窶｢ Medical Screening

End Users Covered:
窶｢ Diagnostics Laboratories
窶｢ Forensic Laboratories
窶｢ Hospitals
窶｢ On-the-spot Testing

Regions Covered:
窶｢ North America
o US
o Canada
o Mexico
窶｢ Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
窶｢ Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
窶｢ South America
o Argentina
o Brazil
o Chile
o Rest of South America
窶｢ Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- ﾂ鮓ｹﾔｭｴｴ share assessments for the regional and country level segments
- ﾂ鮓ｹﾔｭｴｴ share analysis of the top industry players
- Strategic recommendations for the new entrants
- ﾂ鮓ｹﾔｭｴｴ forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
- ﾂ鮓ｹﾔｭｴｴ Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Table Of Contents:

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 ﾂ鮓ｹﾔｭｴｴ Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 End User Analysis
3.8 Emerging ﾂ鮓ｹﾔｭｴｴs
3.9 Futuristic ﾂ鮓ｹﾔｭｴｴ Scenario

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ, By Product
5.1 Introduction
5.2 Analyzers
5.3 Immunoassays Analyzers
5.4 Chromatographic Devices
5.5 Breath Analyzers
5.6 Rapid Testing Devices
5.7 Urine Testing Devices
5.8 Oral Fluid Testing Devices
5.9 Consumables
5.10 Fluid Collection Devices
5.11 Other Products

6 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ, By Sample
6.1 Introduction
6.2 Saliva
6.3 Breath
6.4 Urine
6.5 Blood
6.6 Hair & Sweat

7 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ, By Testing Type
7.1 Introduction
7.2 Work Place Screening
7.3 Pain Management Testing
7.4 Criminal Justice Testing
7.5 Medical Screening

8 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ, By End User
8.1 Introduction
8.2 Diagnostics Laboratories
8.3 Forensic Laboratories
8.4 Hospitals
8.5 On-the-spot Testing

9 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa

10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling
11.1 Atlas link biotech co ltd.
11.2 Beckman coulter, inc
11.3 1st step detect associates, llc
11.4 Biophor diagnostics, inc
11.5 Abbott diagnostics
11.6 Bio-medical products corp
11.7 Accutech, llc
11.8 Bio-rad laboratories
11.9 Alere, inc.
11.10 Bioscan screening systems, inc.
11.11 Alfa scientific designs, inc.
11.12 Branan medical corp
11.13 Amedica biotech, inc
11.14 Confirm biosciences
11.15 American biomedica corporation
11.16 Devon medical products

List of Tables
Table 1 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Region (2016-2026) (US $MN)
Table 2 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Product Type (2016-2026) (US $MN)
Table 3 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Analyzers (2016-2026) (US $MN)
Table 4 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Immunoassays Analyzers (2016-2026) (US $MN)
Table 5 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Chromatographic Devices (2016-2026) (US $MN)
Table 6 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Breath Analyzers (2016-2026) (US $MN)
Table 7 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Rapid Testing Devices (2016-2026) (US $MN)
Table 8 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Urine Testing Devices (2016-2026) (US $MN)
Table 9 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Oral Fluid Testing Devices (2016-2026) (US $MN)
Table 10 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Consumables (2016-2026) (US $MN)
Table 11 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Fluid Collection Devices (2016-2026) (US $MN)
Table 12 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Product (2016-2026) (US $MN)
Table 13 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Sample Type (2016-2026) (US $MN)
Table 14 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Saliva (2016-2026) (US $MN)
Table 15 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Breath (2016-2026) (US $MN)
Table 16 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Urine (2016-2026) (US $MN)
Table 17 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Blood (2016-2026) (US $MN)
Table 18 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, ByHair & Sweat (2016-2026) (US $MN)
Table 19 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Testing Type (2016-2026) (US $MN)
Table 20 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Work Place Screening (2016-2026) (US $MN)
Table 21 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Pain Management Testing (2016-2026) (US $MN)
Table 22 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Criminal Justice Testing (2016-2026) (US $MN)
Table 23 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Medical Screening (2016-2026) (US $MN)
Table 24 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By End User (2016-2026) (US $MN)
Table 25 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Diagnostics Laboratories (2016-2026) (US $MN)
Table 26 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Forensic Laboratories (2016-2026) (US $MN)
Table 27 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Hospitals (2016-2026) (US $MN)
Table 28 Global Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By On-the-spot Testing (2016-2026) (US $MN)
Table 29 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) (US $MN)
Table 30 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Product Type (2016-2026) (US $MN)
Table 31 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Analyzers (2016-2026) (US $MN)
Table 32 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Immunoassays Analyzers (2016-2026) (US $MN)
Table 33 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Chromatographic Devices (2016-2026) (US $MN)
Table 34 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Breath Analyzers (2016-2026) (US $MN)
Table 35 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Rapid Testing Devices (2016-2026) (US $MN)
Table 36 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Urine Testing Devices (2016-2026) (US $MN)
Table 37 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Oral Fluid Testing Devices (2016-2026) (US $MN)
Table 38 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Consumables (2016-2026) (US $MN)
Table 39 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Fluid Collection Devices (2016-2026) (US $MN)
Table 40 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Product (2016-2026) (US $MN)
Table 41 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Sample Type (2016-2026) (US $MN)
Table 42 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Saliva (2016-2026) (US $MN)
Table 43 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Breath (2016-2026) (US $MN)
Table 44 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Urine (2016-2026) (US $MN)
Table 45 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Blood (2016-2026) (US $MN)
Table 46 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, ByHair & Sweat (2016-2026) (US $MN)
Table 47 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Testing Type (2016-2026) (US $MN)
Table 48 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Work Place Screening (2016-2026) (US $MN)
Table 49 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Pain Management Testing (2016-2026) (US $MN)
Table 50 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Criminal Justice Testing (2016-2026) (US $MN)
Table 51 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Medical Screening (2016-2026) (US $MN)
Table 52 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By End User (2016-2026) (US $MN)
Table 53 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Diagnostics Laboratories (2016-2026) (US $MN)
Table 54 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Forensic Laboratories (2016-2026) (US $MN)
Table 55 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Hospitals (2016-2026) (US $MN)
Table 56 North America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By On-the-spot Testing (2016-2026) (US $MN)
Table 57 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) (US $MN)
Table 58 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Product Type (2016-2026) (US $MN)
Table 59 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Analyzers (2016-2026) (US $MN)
Table 60 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Immunoassays Analyzers (2016-2026) (US $MN)
Table 61 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Chromatographic Devices (2016-2026) (US $MN)
Table 62 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Breath Analyzers (2016-2026) (US $MN)
Table 63 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Rapid Testing Devices (2016-2026) (US $MN)
Table 64 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Urine Testing Devices (2016-2026) (US $MN)
Table 65 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Oral Fluid Testing Devices (2016-2026) (US $MN)
Table 66 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Consumables (2016-2026) (US $MN)
Table 67 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Fluid Collection Devices (2016-2026) (US $MN)
Table 68 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Product (2016-2026) (US $MN)
Table 69 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Sample Type (2016-2026) (US $MN)
Table 70 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Saliva (2016-2026) (US $MN)
Table 71 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Breath (2016-2026) (US $MN)
Table 72 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Urine (2016-2026) (US $MN)
Table 73 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Blood (2016-2026) (US $MN)
Table 74 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, ByHair & Sweat (2016-2026) (US $MN)
Table 75 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Testing Type (2016-2026) (US $MN)
Table 76 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Work Place Screening (2016-2026) (US $MN)
Table 77 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Pain Management Testing (2016-2026) (US $MN)
Table 78 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Criminal Justice Testing (2016-2026) (US $MN)
Table 79 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Medical Screening (2016-2026) (US $MN)
Table 80 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By End User (2016-2026) (US $MN)
Table 81 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Diagnostics Laboratories (2016-2026) (US $MN)
Table 82 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Forensic Laboratories (2016-2026) (US $MN)
Table 83 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Hospitals (2016-2026) (US $MN)
Table 84 Europe Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By On-the-spot Testing (2016-2026) (US $MN)
Table 85 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) (US $MN)
Table 86 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Product Type (2016-2026) (US $MN)
Table 87 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Analyzers (2016-2026) (US $MN)
Table 88 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Immunoassays Analyzers (2016-2026) (US $MN)
Table 89 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Chromatographic Devices (2016-2026) (US $MN)
Table 90 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Breath Analyzers (2016-2026) (US $MN)
Table 91 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Rapid Testing Devices (2016-2026) (US $MN)
Table 92 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Urine Testing Devices (2016-2026) (US $MN)
Table 93 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Oral Fluid Testing Devices (2016-2026) (US $MN)
Table 94 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Consumables (2016-2026) (US $MN)
Table 95 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Fluid Collection Devices (2016-2026) (US $MN)
Table 96 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Product (2016-2026) (US $MN)
Table 97 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Sample Type (2016-2026) (US $MN)
Table 98 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Saliva (2016-2026) (US $MN)
Table 99 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Breath (2016-2026) (US $MN)
Table 100 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Urine (2016-2026) (US $MN)
Table 101 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Blood (2016-2026) (US $MN)
Table 102 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, ByHair & Sweat (2016-2026) (US $MN)
Table 103 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Testing Type (2016-2026) (US $MN)
Table 104 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Work Place Screening (2016-2026) (US $MN)
Table 105 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Pain Management Testing (2016-2026) (US $MN)
Table 106 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Criminal Justice Testing (2016-2026) (US $MN)
Table 107 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Medical Screening (2016-2026) (US $MN)
Table 108 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By End User (2016-2026) (US $MN)
Table 109 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Diagnostics Laboratories (2016-2026) (US $MN)
Table 110 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Forensic Laboratories (2016-2026) (US $MN)
Table 111 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Hospitals (2016-2026) (US $MN)
Table 112 Asia Pacific Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By On-the-spot Testing (2016-2026) (US $MN)
Table 113 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) (US $MN)
Table 114 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Product Type (2016-2026) (US $MN)
Table 115 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Analyzers (2016-2026) (US $MN)
Table 116 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Immunoassays Analyzers (2016-2026) (US $MN)
Table 117 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Chromatographic Devices (2016-2026) (US $MN)
Table 118 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Breath Analyzers (2016-2026) (US $MN)
Table 119 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Rapid Testing Devices (2016-2026) (US $MN)
Table 120 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Urine Testing Devices (2016-2026) (US $MN)
Table 121 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Oral Fluid Testing Devices (2016-2026) (US $MN)
Table 122 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Consumables (2016-2026) (US $MN)
Table 123 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Fluid Collection Devices (2016-2026) (US $MN)
Table 124 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Product (2016-2026) (US $MN)
Table 125 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Sample Type (2016-2026) (US $MN)
Table 126 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Saliva (2016-2026) (US $MN)
Table 127 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Breath (2016-2026) (US $MN)
Table 128 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Urine (2016-2026) (US $MN)
Table 129 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Blood (2016-2026) (US $MN)
Table 130 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, ByHair & Sweat (2016-2026) (US $MN)
Table 131 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Testing Type (2016-2026) (US $MN)
Table 132 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Work Place Screening (2016-2026) (US $MN)
Table 133 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Pain Management Testing (2016-2026) (US $MN)
Table 134 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Criminal Justice Testing (2016-2026) (US $MN)
Table 135 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Medical Screening (2016-2026) (US $MN)
Table 136 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By End User (2016-2026) (US $MN)
Table 137 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Diagnostics Laboratories (2016-2026) (US $MN)
Table 138 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Forensic Laboratories (2016-2026) (US $MN)
Table 139 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Hospitals (2016-2026) (US $MN)
Table 140 South America Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By On-the-spot Testing (2016-2026) (US $MN)
Table 141 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) (US $MN)
Table 142 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Product Type (2016-2026) (US $MN)
Table 143 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Analyzers (2016-2026) (US $MN)
Table 144 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Immunoassays Analyzers (2016-2026) (US $MN)
Table 145 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Chromatographic Devices (2016-2026) (US $MN)
Table 146 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Breath Analyzers (2016-2026) (US $MN)
Table 147 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Rapid Testing Devices (2016-2026) (US $MN)
Table 148 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Urine Testing Devices (2016-2026) (US $MN)
Table 149 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Oral Fluid Testing Devices (2016-2026) (US $MN)
Table 150 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Consumables (2016-2026) (US $MN)
Table 151 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Fluid Collection Devices (2016-2026) (US $MN)
Table 152 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Product (2016-2026) (US $MN)
Table 153 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Sample Type (2016-2026) (US $MN)
Table 154 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Saliva (2016-2026) (US $MN)
Table 155 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Breath (2016-2026) (US $MN)
Table 156 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Urine (2016-2026) (US $MN)
Table 157 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Blood (2016-2026) (US $MN)
Table 158 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, ByHair & Sweat (2016-2026) (US $MN)
Table 159 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Testing Type (2016-2026) (US $MN)
Table 160 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Work Place Screening (2016-2026) (US $MN)
Table 161 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Pain Management Testing (2016-2026) (US $MN)
Table 162 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Criminal Justice Testing (2016-2026) (US $MN)
Table 163 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Medical Screening (2016-2026) (US $MN)
Table 164 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By End User (2016-2026) (US $MN)
Table 165 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Diagnostics Laboratories (2016-2026) (US $MN)
Table 166 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Forensic Laboratories (2016-2026) (US $MN)
Table 167 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By Hospitals (2016-2026) (US $MN)
Table 168 Middle East & Africa Drugs Of Abuse Testing ﾂ鮓ｹﾔｭｴｴ Outlook, By On-the-spot Testing (2016-2026) (US $MN)

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

ﾌ�

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

ﾌ�

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.